ATE419834T1 - Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren - Google Patents

Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren

Info

Publication number
ATE419834T1
ATE419834T1 AT01274072T AT01274072T ATE419834T1 AT E419834 T1 ATE419834 T1 AT E419834T1 AT 01274072 T AT01274072 T AT 01274072T AT 01274072 T AT01274072 T AT 01274072T AT E419834 T1 ATE419834 T1 AT E419834T1
Authority
AT
Austria
Prior art keywords
drug
copolymers
vinyl
vinyl acetate
surface stabilizers
Prior art date
Application number
AT01274072T
Other languages
German (de)
English (en)
Inventor
Henry Bosch
Niels Ryde
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Application granted granted Critical
Publication of ATE419834T1 publication Critical patent/ATE419834T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT01274072T 2000-11-20 2001-11-16 Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren ATE419834T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71511700A 2000-11-20 2000-11-20

Publications (1)

Publication Number Publication Date
ATE419834T1 true ATE419834T1 (de) 2009-01-15

Family

ID=24872726

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01274072T ATE419834T1 (de) 2000-11-20 2001-11-16 Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren

Country Status (8)

Country Link
EP (1) EP1341521B1 (https=)
JP (2) JP4541647B2 (https=)
AT (1) ATE419834T1 (https=)
AU (1) AU2001297844A1 (https=)
CA (1) CA2428785C (https=)
DE (1) DE60137362D1 (https=)
ES (1) ES2317874T3 (https=)
WO (1) WO2002094215A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CN101094659A (zh) * 2004-12-31 2007-12-26 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
EA200702595A1 (ru) * 2005-05-23 2008-12-30 Элан Фарма Интернэшнл Лимитед Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов
WO2007046632A1 (en) * 2005-10-18 2007-04-26 Amorepacific Corporation Cationic polymer nanoparticles encapsulating an active ingredients, and the cosmetic composition containing the same
WO2008002485A2 (en) * 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
AU2016203251B2 (en) * 2006-06-30 2017-11-16 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
DK2054042T3 (da) * 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
AU2010239081C1 (en) 2009-04-24 2014-11-06 Iceutica Pty Ltd A novel formulation of indomethacin
MY165826A (en) * 2010-10-01 2018-05-17 Cipla Ltd Pharmaceutical composition
WO2013125232A1 (ja) * 2012-02-23 2013-08-29 キヤノン株式会社 光音響造影剤用色素含有ナノ粒子
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US10022328B2 (en) 2015-02-20 2018-07-17 Cytec Industries Inc. Dialkyl sulfosuccinate compositions, method of making, and method of use
JP7021182B2 (ja) * 2016-03-24 2022-02-16 ロケート・バイオ・リミテッド 足場材料、方法および使用
GB201810925D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and methods of treatment
PL3928772T3 (pl) 2020-06-26 2024-10-07 Algiax Pharmaceuticals Gmbh Kompozycja nanocząstkowa
CA3207235A1 (en) * 2021-01-11 2022-07-14 Bayer Healthcare Llc Concentrated liquid gel formulations containing naproxen salts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
DE59709127D1 (de) * 1996-07-08 2003-02-20 Ciba Sc Holding Ag Triazinderivate als UV-Filter in Sonnenschutzmitteln
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Also Published As

Publication number Publication date
JP4541647B2 (ja) 2010-09-08
WO2002094215A2 (en) 2002-11-28
EP1341521A2 (en) 2003-09-10
AU2001297844A1 (en) 2002-12-03
WO2002094215A3 (en) 2003-05-01
CA2428785C (en) 2011-04-26
DE60137362D1 (de) 2009-02-26
EP1341521B1 (en) 2009-01-07
JP2004520443A (ja) 2004-07-08
CA2428785A1 (en) 2002-11-28
JP2010111685A (ja) 2010-05-20
ES2317874T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
ATE419834T1 (de) Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
DE60332212D1 (de) Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
DE60222160D1 (de) Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
ATE381317T1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
EA200701274A1 (ru) Нанодисперсные составы на основе такролимуса
ATE431131T1 (de) Meloxican-formulierungen in nanoteilchenform
EA200601468A1 (ru) Частицы
ATE509618T1 (de) Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator
ES2191616T3 (es) Polvos pulverizables de fluoropolimeros no fibrilables.
ATE350013T1 (de) Nanopartikelzusammensetzungen enthaltend insulin
ATE419835T1 (de) Nystatin-nanopartikelzusammensetzungen
SG170047A1 (en) Nanoparticulate posaconazole formulations
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
WO2007086914A3 (en) Nanoparticulate clopidogrel formulations
EA200702638A1 (ru) Стабильная композиция (рецептура) с наночастицами ацетаминофена
DE602005027477D1 (de) Arzneimittelabgabe aus embolischen mitteln
HRP20100372T1 (hr) Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba
BR0209020A (pt) Composição farmacêutica de polialilamina
MX2010004171A (es) Composiciones cosmetica que comprende particulas que atrapan solidos para liberacion sostenida de materiales volatiles.
EP1720916A4 (en) RARE METAL AGGREGATE FORMULATION USING DIBLOCK COPOLYMERS
ES2183918T3 (es) Mezclas de resina de metacrilato.
UA94917C2 (ru) Композиции для местного применения
EA200701107A1 (ru) Твердая фармацевтическая композиция, содержащая валсартан
NO20080403L (no) Nanopartikulaere megestrolformuleringer
DE602005025082D1 (de) Nicht-lamellare zubereitungen von dioleoyl-phosphatidyl ethanolamin und polysorbat80

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties